Mental Health

PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market

TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a company...

NetraMark’s AI Significantly Outperforms ChatGPT, DeepSeek and Traditional Machine Learning in Clinical Trial Subpopulation Discovery, Offers New Path for Trial Success

TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)...

As Sober.Buzz Community Explodes Its Growth Globally it is Announcing “Spreading the Good BUZZ” Podcast Hosted by Josh Case Debuting July 7th

Sober.Buzz's Online Store that includes the Exclusive Inspirational Collection by Heidi Case has Launched. Additionally, the much-anticipated Public Sale of...

New Study Reveals Americans Lost 120 Total Nights of Sleep Over a Five-Year Period, Negatively Impacting Cardiovascular Health, Weight and Longevity

Data from connected health wearables company, Withings, shows how poor sleep impacts cardiovascular risk and longevity across the US –...

PharmaTher Applauds FDA’s New Commissioner’s National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and National Security Applications

error: Content is protected !!